AUROPHARMA vs WINDLAS: Stock Comparison
AUROBINDO PHARMA is the larger company by market capitalisation. AUROBINDO PHARMA shows a lower P/E and a higher net margin, while WINDLAS BIOTECH shows a higher ROE, a higher dividend yield and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
AUROPHARMA leads 8; WINDLAS leads 5 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | AUROPHARMA | WINDLAS |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | AUROPHARMA | WINDLAS |
|---|---|---|
| Live Price | ₹1,653.1 | ₹1,126.35 |
| Day Change | 0.97% | -0.07% |
| Volume | 5.74 L | 1.91 L |
| 52-Week High | ₹1,717 | ₹1,148 |
| 52-Week Low | ₹1,033.1 | ₹697.4 |
| Distance from 52W High | -3.72% | -1.89% |
Valuation
| Metric | AUROPHARMA | WINDLAS |
|---|---|---|
| Market Cap | ₹95,127 Cr | ₹2,310 Cr |
| P/E Ratio | 25.84x | 43.22x |
| P/B Ratio | 2.54x | 3.63x |
| EPS | ₹17.95 | ₹8.55 |
| Book Value | ₹658.4 | ₹281.47 |
| Dividend Yield | 0% | 0.64% |
Growth
| Metric | AUROPHARMA | WINDLAS |
|---|---|---|
| Revenue Growth (TTM YoY) | 5.6% | 17.7% |
| EPS Growth (TTM YoY) | 1.9% | -2.6% |
| Qtr Sales Growth | 226.86% | 4.03% |
| Qtr Profit Growth | 39.99% | 10.4% |
Profitability & Leverage
| Metric | AUROPHARMA | WINDLAS |
|---|---|---|
| ROE | 9.25% | 11.44% |
| ROCE | 10.23% | 11.95% |
| Net Margin | 10.62% | 7.35% |
| Operating Margin | 16.33% | 10.15% |
| Debt to Equity | 0.2x | 0.05x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | AUROPHARMA | WINDLAS |
|---|---|---|
| Promoter Holding | 48.81%▲ 0.06 pp | 63.31%▲ 1.41 pp |
| FII Holding | 16.38%▲ 1.14 pp | 2.04%▲ 1.44 pp |
| DII Holding | 25.1%▼ 0.77 pp | 9.84%▼ 1.97 pp |
| Public Holding | 6.64%▼ 0.44 pp | 24.8%▼ 0.9 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: AUROBINDO PHARMA and WINDLAS BIOTECH.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.